Page 305 - Drug Class Review

Drug Effectiveness Review Project
The trials studied different dosages of MEM with placebo. The doses ranged from 10 to 30 mg/day but the
most common was 20mg/day. Most of the trials started with low doses progressively increased to target
levels. Outcome measures included ADAS-Cog, Syndrom-Kurz test, SIB, CIBIC-plus, CGIC, SCAG,
Note: This study stratifies results by the randomized population (i.e., AD, VaD, or AD+VaD)
NOSIE, ADCS-ADL, ADL, BGP, NOSGER

Cognition: Moderate-Severe AD: Significant improvement in SIB at 28 weeks (1 trial; *MD = 6.1; 95% CI: 2.99 – 9.21; P = 0.0001) Mild-moderate VaD: Significant improvement in ADAS-Cog at 28 weeks (2 trials; **WMD = -2.19; 95% CI: -3.16 – -1.21; P < 0.0001) Mixed AD + VaD: Effect size NR at 12 weeks (1 trial) Activities of Daily Living: Moderate-Severe AD: Significant improvement in activities of daily living at 28 weeks (1 trial; WMD=0.32; 95% CI: 0.07 – 0.73; P = 0.01) Mild-moderate VaD: No significant differences in activities of daily living (NOSGER) (1 trial;

• • •

Final Report Update 1 Authors: Areosa et al. Year: 2004 CHARACTERISTICS OF INTERVENTIONS: MAIN RESULTS: Alzheimer's Drugs